Description

Description

Gvia-Et (15/100mg) is a combination diabetes medication manufactured by Genix Pharma, containing two active substances, Ertugliflozin and Sitagliptin, in a single film-coated tablet. This pack contains 14 tablets and is formulated for individuals living with type 2 diabetes mellitus who require more than one blood-sugar-lowering agent to achieve adequate glycemic control. This particular strength provides a higher dose of Ertugliflozin compared to the 5/100mg variant, and it is typically considered for patients whose blood sugar levels require a more pronounced SGLT2 inhibitor effect alongside Sitagliptin. By combining a DPP-4 inhibitor with an SGLT2 inhibitor in one tablet, Gvia-Et offers two distinct approaches to lowering blood sugar within a single, more convenient dosing routine. It is intended for use as part of a broader diabetes management plan that typically also includes dietary control, regular physical activity, and routine blood glucose monitoring, all under the supervision of a qualified physician.

Ingredients

Each Gvia-Et (15/100mg) tablet contains Ertugliflozin, present as Ertugliflozin L-Pyroglutamic Acid, at a strength of 15mg, along with Sitagliptin, present as Sitagliptin Phosphate Monohydrate, at a strength of 100mg. The tablet core also typically includes standard pharmaceutical excipients such as binders, fillers, and a film-coating layer, which help with tablet stability, appearance, and ease of swallowing. The exact inactive ingredient list may be confirmed by checking the printed leaflet inside the pack, as formulations can occasionally be refined by the manufacturer.

Dosage Form

Gvia-Et is supplied as an oral film-coated tablet. Each box contains 14 tablets, typically arranged in blister strips for protection against moisture and light. The film coating is designed to mask taste and support easier swallowing compared to an uncoated tablet.

Uses

Gvia-Et is primarily used to improve blood glucose control in adults diagnosed with type 2 diabetes mellitus. The two components work through different but complementary pathways to achieve this effect. Ertugliflozin belongs to a class of medicines known as SGLT2 inhibitors, and it works by blocking the reabsorption of glucose in the kidneys, allowing excess sugar to be removed from the body through urine. Sitagliptin belongs to a class of medicines known as DPP-4 inhibitors, and it works by increasing the levels of certain natural hormones called incretins, which help the body produce more insulin when blood sugar is high while also reducing the amount of sugar produced by the liver. Together, this combination is generally prescribed for patients whose blood sugar is not adequately controlled on a single agent alone, or as directed by a treating physician based on individual health assessment and the appropriate Ertugliflozin strength required.

How to Use

Gvia-Et should only be taken exactly as prescribed by a doctor. It is generally recommended to take the tablet once daily in the morning, with or without food, though a doctor’s specific instructions should always be followed. The tablet should be swallowed whole with a glass of water and should not be crushed, split, or chewed unless specifically advised otherwise by a healthcare provider. Adequate fluid intake is generally encouraged while taking this medicine, given its effect on urinary glucose excretion. Dosage and frequency will vary depending on individual blood sugar levels, kidney function, other medications being taken, and overall health status, so patients should never adjust their dose without medical guidance. Missing a dose should not be compensated for by taking a double dose at the next scheduled time.

Side Effects

As with any medication, Gvia-Et may cause side effects in some individuals, though not everyone will experience them. Commonly reported effects may include genital yeast infections, urinary tract infections, increased urination, and mild headache, particularly when treatment is first started. Less commonly, some patients may experience thirst, dizziness related to fluid loss, or mild digestive discomfort. In rare cases, more serious effects such as signs of dehydration, a sudden drop in blood pressure, symptoms of ketoacidosis such as nausea and unusual fatigue, or symptoms of pancreatitis marked by persistent abdominal pain may occur and should be reported to a doctor immediately. This information is not exhaustive, and patients should read the enclosed leaflet or consult their physician or pharmacist for complete safety information.

Pregnancy & Breastfeeding

The safety of Gvia-Et during pregnancy and breastfeeding has not been firmly established for this specific combination. Diabetes management during pregnancy typically requires a different, carefully individualized treatment approach, and this medicine should not be used by pregnant women or those planning pregnancy unless specifically advised by a treating physician. Similarly, women who are breastfeeding should consult their doctor before use, as it is not fully known whether these components pass into breast milk. Medical supervision is essential in both situations.

Storage Instructions

Gvia-Et tablets should be stored at room temperature, generally below 30°C, away from direct sunlight, excessive heat, and moisture. The medicine should be kept in its original blister pack until the time of use, and it should be stored out of reach of children. The tablets should not be used beyond the expiry date printed on the packaging, and any unused or expired medication should be disposed of responsibly rather than discarded in regular household waste.

FAQS

Q: Why might Gvia-Et increase the frequency of urination?
Because Ertugliflozin works by removing excess glucose through the urine, increased urination is a common and expected effect, though a doctor should be informed if it becomes bothersome.

Q: Is Gvia-Et suitable for type 1 diabetes?
No, this combination is intended for type 2 diabetes management only.

Q: How is the 15/100mg strength different from the 5/100mg strength?
The Sitagliptin dose remains the same at 100mg, while the Ertugliflozin component is higher at 15mg, which may be prescribed based on individual blood sugar control needs as determined by a doctor.

Q: Does Gvia-Et interact with other medicines?
Yes, it may interact with certain other drugs, including diuretics and other diabetes medications. Always inform your doctor of all medications and supplements you are currently taking.

Disclaimer

Always use this medicine strictly according to your doctor’s instructions and prescribed dosage.